— Know what they know.
/
Not Investment Advice

CRL

NYSE · USD
Charles River Laboratories International, Inc.
Healthcare · Medical - Diagnostics & Research
CEO Birgit Girshick Employees 19,700 R&D / revenue 0.0%
Last price
$300.15−1.99%last session
Market cap
$14.5B
P/E (TTM)
n/m
From 52w high
−9.9%
From 52w low
+105.3%
1-year return
+71.6%
RSI 14 · vs SMA200
55.7 · +39.5%
IS score
27.0/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

CRL   SPY   XLV (sector ETF) · weekly closes
80100120140160180Jan 26Apr 26Jul 26Oct 26CRL 172XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
18
Profitability
32
Growth
28
Value
35
Momentum
50
Risk (safety)
41
Quality
31
Balance sheet
43
Earnings quality

Flags

Strengths
✓ Insider buying
Warnings
None of the computed warning flags fires for CRL (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Weak, Efficient ScalePiotroski 4 / 9Altman Z 2.2Beta 1.413 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
1
$0.00M bought
Form 144 notices (12m): 10, $32.8M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
0
No disclosed purchases
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+14
79 new holders, 61 closed
573 filers hold 118.2% · 195 added, 205 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+36
547 funds adding shares
511 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
63.1%
20-day avg 61.0%, 50-day avg 50.5%
Latest 2.1 pp over its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$4.0B
Revenue growth YoY−0.9%
Gross margin30.5%
Operating income$507.8M
Operating margin12.6%
Net income−$144.3M
Net margin-3.6%
EPS (diluted)$-2.91
Cash flow
Operating cash flow$737.6M
Capital expenditure$219.2M
Free cash flow$518.5M
FCF conversion (FCF / OCF)70.3%
Stock-based compensation$71.1M
FCF less SBC$447.4M
Buybacks$360.7M
Dividends$0
Balance sheet & returns
Cash & short-term investments$213.8M
Total debt$2.6B
Net debt$2.4B
Shareholders' equity$3.2B
Goodwill & intangibles$3.1B
Debt / equity1.07
ROE (TTM)-7.7%
ROIC (TTM)7.7%
Operating margin by fiscal year
16.7%FY202116.4%FY202214.9%FY20235.6%FY202410.7%FY2025
Revenue $3.5B (FY2021) to $4.0B (FY2025), a 3.2% CAGR.

Valuation

P/E (TTM)n/m
EV / EBITDA78.4x
Price / sales3.62x
Price / FCF39.0x
FCF yield2.56%
Buyback yield2.49%
SBC / revenue1.6%
Price / book5.12x
Forward P/E FY202626.4x
Forward P/E FY202627.3x
Forward P/E FY202723.4x
Forward multiples divide today's price by Street EPS estimates. Street mean target $315.00 across 17 analysts last quarter is theirs, not ours.

CRL vs industry median

126 companies in Medical - Diagnostics & Research
Gross margin 32.2% 48.5% Operating margin 12.3% -9.4% Net margin -6.0% -9.5% ROIC 7.7% -2.5%
CRL (TTM)Industry median Asset turnover 0.53 vs industry 0.54 · financial leverage 2.65

Earnings delivery

Next report 2026-11-04 · consensus EPS $2.97
100%
beat rate, 12 of 12 quarters
+8.6%
median EPS surprise
12
longest beat streak
+16+3+10+17+7+6+14+25+5+3+5+10
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-08 to 2026-08-05. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
CRL Charles River Laboratories I $14.5Bn/m-7.7%-6.0%−0.9% +71.6%
ICLR ICON Public Limited Company $13.1B39.7x3.5%3.5%+2.0% −9.7%
RVTY Revvity, Inc. $17.0B72.7x3.2%7.1%+5.5% +62.5%
MEDP Medpace Holdings, Inc. $17.3B35.6x162.2%17.2%+24.7% +18.7%
EXAS Exact Sciences Corporation $20.0Bn/m-8.7%-9.8%+17.7% +96.4%
GH Guardant Health, Inc. $21.3Bn/m171.6%-35.9%+42.7% —
QGEN Qiagen N.V. $9.5B23.7x11.9%19.3%+3.0% —
LH Labcorp Holdings Inc. $25.8B26.1x11.7%8.0%+6.4% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-09-24Regulation FD; Exhibits
2026-08-05Earnings Release; Exhibits
2026-05-07Earnings Release; Exhibits
2026-02-25Regulation FD Disclosure
2026-02-18Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits
2026-02-18Results of Operations and Financial Condition; Financial Statements and Exhibits

Context

Shares outstanding48,167,727
Free float98.0%
Institutional ownership118.2%
Beta1.41
Dividend yield0.00%
Last dividendNone on file
50 / 200-day average$288.19 / $214.60
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where CRL sits among 30 scored companies in Medical - Diagnostics & Research (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureCRLIndustry medianIndustry percentileSector median
P/E (TTM) —
PEG (P/E ÷ 3-yr EPS CAGR) —
Price / sales 3.6x 5.7x
34th		 3.7x
Price / book 5.1x 4.1x
59th		 3.6x
Price / tangible book —
Price / free cash flow 39.0x 34.4x
74th		 21.2x
Price / operating cash flow 24.8x 26.0x
48th		 17.1x
Enterprise value $17.3B $16.3B
55th		 $2.5B
EV / sales 4.3x 5.9x
38th		 3.8x
EV / EBITDA 78.4x 25.4x
86th		 16.2x
EV / EBIT —
EV / free cash flow 46.7x 35.1x
79th		 24.6x
Earnings yield -1.6% 1.7%
31st		 -0.3%
FCF yield 2.6% 2.5%
52nd		 1.7%
Operating cash flow yield 4.0% 3.2%
62nd		 2.9%
Graham number (per share) —

Profitability (TTM)

MeasureCRLIndustry medianIndustry percentileSector median
Gross margin 32.2% 52.9%
28th		 65.1%
EBITDA margin 5.5% 15.0%
34th		 6.6%
Operating margin 12.3% 11.0%
59th		 3.5%
EBIT margin -1.9% 9.1%
34th		 2.4%
Net margin -6.0% 7.5%
31st		 0.3%
NOPAT margin 9.8% 9.5%
52nd		 2.7%
FCF margin 9.3% 9.2%
52nd		 4.3%
Operating cash flow margin 14.6% 15.0%
48th		 7.1%
R&D / revenue 0.0% 7.2%
0th		 12.4%
SG&A / revenue 18.8% 29.8%
24th		 37.9%
Stock comp / revenue 1.6% 1.8%
39th		 4.5%
Effective tax rate 21.0% 20.5%
52nd		 21.0%

Returns on capital

MeasureCRLIndustry medianIndustry percentileSector median
ROE (on average equity) -7.7% 4.7%
22nd		 0.8%
ROA -3.2% 3.2%
34th		 -0.3%
ROIC 6.9% 5.6%
55th		 5.5%
ROCE -1.2% 4.0%
34th		 2.3%
Return on tangible assets -1.0% 3.5%
34th		 1.7%
Cash ROIC (OCF / invested capital) 10.3% 11.8%
41st		 9.7%
Gross profitability (GP / assets) 17.1% 22.3%
38th		 29.9%
ROIC, 3-yr average 3.7% 3.7%
50th		 2.6%
ROIC, 5-yr average 5.7% 5.7%
50th		 3.2%
ROE, 5-yr average 6.6% 3.1%
56th		 -4.9%
Incremental ROIC -163.5% -3.0%
7th		 17.2%

Growth

MeasureCRLIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) -0.7% 8.1%
11th		 10.5%
Revenue growth (QoQ) 0.8% 8.1%
7th		 7.2%
Revenue CAGR, 3 yr -1.5% 4.9%
11th		 10.7%
Revenue CAGR, 5 yr 4.1% 7.0%
44th		 12.1%
Gross profit CAGR, 3 yr -5.9% 5.3%
15th		 10.6%
Operating income CAGR, 3 yr -8.6% 6.4%
20th		 11.7%
Net income growth (TTM YoY) —
Net income CAGR, 3 yr —
EPS growth (TTM YoY) —
EPS CAGR, 3 yr —
EPS CAGR, 5 yr —
FCF growth (TTM YoY) -35.9% 12.4%
0th		 18.6%
FCF CAGR, 3 yr 8.6% 7.7%
57th		 15.4%
Operating cash flow CAGR, 3 yr -2.3% 8.0%
6th		 11.9%
Book value CAGR, 3 yr -2.5% 2.6%
28th		 2.1%
Dividend CAGR, 3 yr —
Sustainable growth rate —

Margin history & stability

MeasureCRLIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 33.2% 53.7%
32nd		 62.6%
Operating margin, 3-yr average 9.7% 8.7%
54th		 1.0%
Net margin, 3-yr average 1.0% 4.1%
46th		 -2.6%
FCF margin, 3-yr average 11.9% 10.5%
54th		 3.2%
Revenue stability (0-1) 0.48 0.82
18th		 0.80
Earnings stability (0-1) 0.67 0.46
79th		 0.37
Margin stability (0-1) 0.93 0.93
50th		 0.93

Liquidity (latest quarter)

MeasureCRLIndustry medianIndustry percentileSector median
Cash & short-term investments $192.0M $520.8M
17th		 $330.9M
Net cash (− = net debt) −$2.8B −$874.6M
21st		 $8.4M
Working capital $394.4M $404.8M
48th		 $381.1M
Current ratio 1.35 2.13
17th		 3.02
Quick ratio 1.04 1.77
17th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.17 0.96
10th		 1.43
Defensive interval (days) 415 days 466 days
41st		 415 days

Leverage & solvency (latest quarter)

MeasureCRLIndustry medianIndustry percentileSector median
Total debt $3.0B $1.7B
69th		 $289.1M
Debt / equity 1.07 0.50
89th		 0.45
Net debt / equity 1.00 0.30
89th		 −0.13
Debt / assets 40.2% 28.5%
83rd		 24.4%
Debt / capital 51.6% 33.6%
86th		 31.1%
Debt / EBITDA 13.73 3.30
95th		 2.62
Net debt / EBITDA 12.86 2.39
95th		 1.42
Interest coverage (EBIT / interest) −0.7x 2.9x
36th		 2.1x
Cash interest coverage 5.5x 6.7x
40th		 3.6x
Debt payback (years of OCF) 5.2 yrs 3.8 yrs
70th		 2.7 yrs
Liabilities / assets 62.2% 45.2%
79th		 49.8%
IS credit model rating BB- — —
Implied credit spread (bps) 550 175
79th		 225

Efficiency

MeasureCRLIndustry medianIndustry percentileSector median
Asset turnover 0.53 0.56
45th		 0.56
Fixed asset turnover 2.19 4.31
14th		 4.87
Inventory turnover 8.7 7.2
68th		 2.7
Receivables turnover 6.3 6.5
41st		 6.4
Days sales outstanding 58 days 56 days
59th		 57 days
Days inventory outstanding 42 days 51 days
32nd		 136 days
Days payables outstanding 19 days 45 days
14th		 59 days
Cash conversion cycle (days) 81 days 67 days
62nd		 70 days
Capex / revenue 5.3% 3.4%
72nd		 2.6%
Capex / depreciation 0.71 0.69
55th		 0.55
Operating expense ratio 24.2% 45.1%
28th		 56.5%

Cash flow & earnings quality

MeasureCRLIndustry medianIndustry percentileSector median
Operating cash flow / net income —
FCF / net income —
FCF / operating cash flow 63.7% 76.8%
26th		 81.2%
Capex / operating cash flow 36.3% 23.2%
74th		 18.8%
Accruals ratio -10.9% -4.3%
21st		 -5.4%
Sloan accruals ratio -3.9% -1.5%
28th		 -1.3%
Earnings quality score (0-1) —

Dividends & buybacks

MeasureCRLIndustry medianIndustry percentileSector median
Dividend yield 0.0% 0.0%
0th		 0.0%
Dividend per share (TTM) $0.00 $0.00
0th		 $0.00
Payout ratio (dividends / net income) —
Dividends / FCF 0.0% 0.0%
0th		 0.0%
Dividend growth (YoY) —
Buyback yield 2.2% 0.9%
72nd		 0.0%
Shareholder yield (dividends + buybacks) 2.2% 1.1%
66th		 0.0%
Share count change (YoY) -1.7% -0.7%
36th		 2.0%
Buybacks, last 5 years $1.7B $129.7M
55th		 $0

Scores & forensic checks

MeasureCRLIndustry medianIndustry percentileSector median
IS score 27 50
7th		 46
IS profitability 18 36
24th		 22
IS growth 32 55
11th		 60
IS value 28 40
3rd		 39
IS momentum 35 72
4th		 67
IS risk (safety) 50 80
21st		 80
IS quality 41 62
14th		 49
IS balance sheet 31 51
24th		 55
IS earnings quality 43 69
14th		 56
IS cash flow 30 50
38th		 41
Piotroski F-score (0-9) 4 6
7th		 5
Altman Z-score 2.2 3.4
31st		 3.2
Beneish M-score −3.11 −2.60
7th		 −2.62
Ohlson O-score −6.42 −8.12
72nd		 −7.16
IS credit score 35 67
17th		 62

Per share

MeasureCRLIndustry medianIndustry percentileSector median
EPS, diluted (TTM) −$4.92 $1.54
3rd		 −$0.03
Book value per share $58.57 $17.72
72nd		 $7.10
Tangible book per share −$9.98 $0.32
31st		 $1.91
Revenue per share $82.48 $26.05
76th		 $9.38
FCF per share $7.64 $2.08
69th		 $0.46
Operating cash flow per share $12.01 $3.59
72nd		 $0.93
Cash per share $3.96 $6.18
28th		 $3.51

Size (TTM)

MeasureCRLIndustry medianIndustry percentileSector median
Market cap $14.5B $13.8B
52nd		 $2.4B
Revenue $4.0B $2.5B
62nd		 $770.2M
EBITDA $220.5M $438.4M
45th		 $56.1M
Net income −$238.5M $139.0M
7th		 −$3.3M
Free cash flow $370.6M $268.0M
52nd		 $41.2M
Total assets $7.5B $3.4B
69th		 $1.3B
Shareholders' equity $2.8B $1.5B
66th		 $568.4M
Employees 19,000 6,319
79th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-10-05Parisotto Shannon M
CEVP, Disc & Safety Assessment
 Option exercise 981$208.44$204,4805,788
2026-10-05Parisotto Shannon M
CEVP, Disc & Safety Assessment
 Open-market sale 981$308.44$302,5804,807
2026-10-05Parisotto Shannon M
CEVP, Disc & Safety Assessment
 Option exercise 981$208.44$204,4802,944
2026-09-30Coleman Glenn
EVP & Chief Financial Officer
 Open-market buy 10$297.43$2,97427,762
2026-08-25Foster James C
Director
 Option exercise 21,132$194.12$4.1M52,728
2026-08-25Foster James C
Director
 Option exercise 12,429$208.44$2.6M65,157
2026-08-25Foster James C
Director
 Open-market sale 33,561$300.00$10.1M31,596
2026-08-25Foster James C
Director
 Option exercise 21,132$194.12$4.1M7,044
2026-08-25Foster James C
Director
 Option exercise 12,429$208.44$2.6M12,429
2026-08-19Girshick Birgit
Director, Chief Executive Officer
 Gift 528——35,485
2026-08-19Parisotto Shannon M
CEVP, Disc & Safety Assessment
 Option exercise 2,039$194.12$395,8116,846
2026-08-19Parisotto Shannon M
CEVP, Disc & Safety Assessment
 Open-market sale 2,039$294.12$599,7114,807

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunAugSepOct

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired2475,891$13.3M
GiftDisposed8193,025—
GiftAcquired6192,240—
Open-market buyAcquired110$2,974
Open-market saleDisposed19166,971$42.9M
Option exerciseAcquired1282,625$15.6M
Option exerciseDisposed1282,625$15.6M
Tax withholdingDisposed258,120$1.4M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 10 notices · 133,410 shares · $32.8M
FiledFilerShares proposedEst. proceeds
2026-10-05Parisotto Shannon M981$308,580
2026-08-19Parisotto Shannon M2,039$599,711
2026-08-18Nancy C Andrews573$163,305
2026-08-11Parisotto Shannon M3,714$1.0M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 0 trades (0 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2025-05-15Rob BresnahanHouseSale$1,001 - $15,0002025-06-02
2025-05-14Robert P. BresnahanHouseSale (Full)$1,001 - $15,0002025-06-02
2025-05-12Jefferson ShreveHouseSale$15,001 - $50,0002025-06-23
2025-05-11Jefferson ShreveHouseSale (Full)$15,001 - $50,0002025-06-23
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
FMR LLC4,239,752$961.5M8.80%
BlackRock, Inc.3,798,560$861.5M7.89%
VANGUARD CAPITAL MANAGEMENT LLC3,149,288$714.2M6.54%
Invesco Ltd.2,984,785$676.9M6.20%
VANGUARD PORTFOLIO MANAGEMENT LLC2,210,979$501.4M4.59%
Allspring Global Investments Holdings, LLC1,882,946$431.4M3.91%
STATE STREET CORP1,864,284$422.8M3.87%
DIMENSIONAL FUND ADVISORS LP1,648,450$373.8M3.42%
ARIEL INVESTMENTS, LLC1,506,185$341.6M3.13%
PRICE T ROWE ASSOCIATES INC /MD/1,505,370$341.4M3.13%
GEODE CAPITAL MANAGEMENT, LLC1,305,738$295.6M2.71%
WELLINGTON MANAGEMENT GROUP LLP1,288,463$292.2M2.67%
CITADEL ADVISORS LLC1,193,601$270.7M2.48%
BANK OF AMERICA CORP /DE/1,172,586$265.9M2.43%
EARNEST PARTNERS LLC1,120,011$254.0M2.33%

Institutional ownership by quarter

2023-092026-06118.2%
% of shares held by 13F filers
2023-092026-06573
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-30573118.2%7919520561
2026-03-31559117.9%7219219987
2025-12-31586109.1%11917720678
2025-09-30554104.0%9819018957
2025-06-30521105.0%91176201129
2025-03-31567110.2%70190244131
2024-12-31640109.4%10217928182
2024-09-30630107.5%6820427296
2024-06-30665108.1%7426623580
2024-03-31678107.8%9325722849
2023-12-31638107.4%9820126071
2023-09-30623106.9%8123021862

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-09-08SCHEDULE 13G/AAbigail P. Johnson10.2%4,865,628
2026-08-13SCHEDULE 13GInvesco Ltd.6.2%2,984,785
2026-08-06SCHEDULE 13G/AAbigail P. Johnson8.8%4,239,751
2026-05-06SCHEDULE 13GAbigail P. Johnson7.0%3,456,245
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
FCNKX0.30%$526.1M
FCNTX0.30%$526.1M
VITSX0.02%$447.3M
VTI0.02%$447.3M
VSMPX0.02%$447.3M
VTSAX0.02%$447.3M

Share structure

Shares outstanding48,167,727
Float47,204,893
Free float98.0%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$3.5B$4.0B$4.1B$4.0B$4.0B
Cost of revenue$2.2B$2.5B$2.6B$2.7B$2.8B
Gross profit$1.3B$1.5B$1.5B$1.3B$1.2B
R&D$0$0$0$0$0
SG&A$619.9M$665.1M$747.9M$751.0M$743.1M
Operating income$589.9M$651.0M$617.3M$227.3M$507.8M
EBITDA$820.2M$986.1M$1.0B$581.1M$911.2M
Pretax income$480.7M$623.0M$581.3M$93.1M−$99.5M
Income tax$81.9M$130.4M$100.9M$67.8M$42.7M
Net income$391.0M$486.2M$474.6M$10.3M−$144.3M
EPS, diluted$7.60$9.48$9.22$0.20$-2.91
Diluted shares51.4M51.3M51.5M51.6M49.6M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$246.3M$233.9M$276.8M$194.6M$213.8M
Receivables$650.4M$752.4M$780.4M$720.9M$708.9M
Inventory$199.1M$255.8M$380.3M$278.5M$299.1M
Total current assets$1.3B$1.4B$1.6B$1.4B$1.4B
PP&E, net$1.6B$1.9B$2.0B$2.0B$2.0B
Goodwill & intangibles$3.8B$3.8B$4.0B$3.6B$3.1B
Total assets$7.0B$7.6B$8.2B$7.5B$7.1B
Accounts payable$198.1M$205.9M$168.9M$140.3M$148.8M
Total current liabilities$1.0B$1.1B$1.1B$994.1M$1.1B
Long-term debt$2.9B$2.7B$2.6B$2.2B$2.5B
Total liabilities$4.4B$4.6B$4.5B$4.0B$3.9B
Shareholders' equity$2.6B$3.0B$3.7B$3.5B$3.2B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$398.8M$492.6M$480.4M$25.3M−$142.2M
Depreciation & amortization$265.5M$303.9M$314.1M$361.7M$403.3M
Stock-based compensation$71.5M$73.6M$72.0M$69.9M$71.1M
Change in working capital$42.9M−$152.6M−$102.4M−$30.3M$14.1M
Operating cash flow$760.8M$619.6M$683.9M$734.6M$737.6M
Capital expenditure−$228.8M−$324.7M−$318.5M−$233.0M−$219.2M
Free cash flow$532.0M$294.9M$365.4M$501.6M$518.5M
Investing cash flow−$1.4B−$607.9M−$563.2M−$245.1M−$209.3M
Net debt issued / repaid$670.0M$19.8M−$75.3M−$412.2M−$121.8M
Buybacks−$40.7M−$38.7M−$24.2M−$119.2M−$360.7M
Dividends paid$0$0$0$0$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin37.7%36.8%36.4%32.9%32.9%
Operating margin16.7%16.4%14.9%5.6%10.7%
Net margin11.0%12.2%11.5%0.3%-3.6%
FCF margin15.0%7.4%8.8%12.4%12.9%
ROE16.8%17.6%14.4%0.3%-4.4%
ROIC8.9%8.8%8.0%1.0%5.6%
ROA6.2%6.6%6.0%0.1%-2.0%
Debt / equity1.261.040.850.790.97
Interest coverage7.5x11.5x5.3x1.7x0.1x
Current ratio1.231.321.521.411.29
Revenue growth+21.1%+12.3%+3.9%−1.9%−0.9%
EPS growth+6.2%+24.8%−2.9%−97.8%−1,556.5%
P/E at year end49.7x23.0x25.7x916.8xn/m
EV / EBITDA at year end27.3x14.3x14.5x20.6x31.3x
FCF yield at year end2.74%2.63%2.99%5.31%5.17%
Dividend payout0.0%0.0%0.0%0.0%—

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Discovery and Safety Assessment$2.1B$2.4B$2.6B$2.5B$2.4B
Research Models and Services$690.4M$739.2M$792.3M$829.4M$846.1M
Manufacturing Support$742.5M$789.6M$721.4M$769.3M$766.4M

Revenue by region · FY2025

UNITED STATES$2.1B · 54%
Europe$1.1B · 28%
CANADA$501.0M · 13%
Asia Pacific$205.0M · 5%

Street estimates by fiscal year

Next report 2026-11-04 · consensus EPS $2.97 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$3.9B$3.9B – $4.0B$11.38$11.19 – $11.501026.4x
2026$4.1B$4.1B – $4.1B$11.00$10.19 – $11.331027.3x
2027$4.0B$4.0B – $4.1B$12.80$12.09 – $13.051023.4x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-05$2.74$3.02+10.2%$977.2M$1.0B+2.8%
2026-05-07$1.96$2.06+5.1%$977.5M$995.8M+1.9%
2026-02-18$2.33$2.39+2.6%$987.0M$994.2M+0.7%
2025-11-05$2.32$2.43+4.7%$987.2M$1.0B+1.8%
2025-08-06$2.50$3.12+24.8%$968.9M$1.0B+6.5%
2025-05-07$2.06$2.34+13.6%$958.8M$984.2M+2.6%
2025-02-19$2.50$2.66+6.4%$948.2M$1.0B+5.7%
2024-11-06$2.42$2.59+7.0%$976.0M$1.0B+3.5%
2024-08-07$2.39$2.80+17.2%$1.0B$1.0B+0.2%
2024-05-09$2.06$2.27+10.2%$992.3M$1.0B+1.9%
2024-02-14$2.39$2.46+2.9%$991.2M$1.0B+2.2%
2023-11-08$2.35$2.72+15.7%$1.0B$1.0B+2.6%
2023-08-09$2.63$2.69+2.3%$1.1B$1.1B+0.6%
2023-05-11$2.59$2.78+7.3%$986.4M$1.0B+4.4%
2023-02-22$2.75$2.98+8.4%$1.0B$1.1B+6.3%
2022-11-02$2.51$2.63+4.8%$970.4M$989.2M+1.9%
2022-08-03$2.73$2.77+1.5%$995.2M$973.1M−2.2%
2022-05-04$2.71$2.75+1.5%$910.1M$913.9M+0.4%
2022-02-16$2.43$2.49+2.5%$888.3M$905.0M+1.9%
2021-11-03$2.57$2.70+5.1%$850.6M$895.9M+5.3%
2021-08-04$2.39$2.61+9.2%$880.4M$914.6M+3.9%
2021-05-04$2.19$2.53+15.5%$798.5M$824.6M+3.3%
2021-02-17$2.11$2.39+13.3%$756.6M$791.0M+4.5%
2020-10-29$1.80$2.33+29.4%$574.2M$743.3M+29.4%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.206-150.306-220.306-290.307-060.307-130.307-200.307-270.508-030.508-100.608-170.508-240.408-31
Week ofNotionalSharesTrades
2026-08-31$385.6M1,338,95939,746
2026-08-24$464.9M1,566,60542,951
2026-08-17$573.4M1,975,08745,166
2026-08-10$497.0M1,774,39645,203
2026-08-03$472.1M1,887,86550,171
2026-07-27$331.3M1,418,21838,252

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1563.1%
DateShort shareShort volumeTotal volume
2026-10-1563.1%209,581332,153
2026-10-1470.9%273,565386,071
2026-10-1356.1%171,620305,794
2026-10-1256.2%143,527255,479
2026-10-0971.2%208,641293,121
2026-10-0847.5%268,676565,131
2026-10-0766.7%315,835473,169
2026-10-0673.6%670,302910,359
2026-10-0567.5%434,622644,256
2026-10-0257.5%97,888170,136
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+2.6Jan+0.7Feb+0.0Mar-3.1Apr+2.7May+2.1Jun+4.1Jul-0.9Aug+0.3Sep-1.3Oct-0.5Nov+3.2Dec
MonthAvg returnUp yearsYears
Jan+2.6%65%20
Feb+0.7%55%20
Mar+0.0%71%21
Apr−3.1%45%20
May+2.7%70%20
Jun+2.1%55%20
Jul+4.1%65%20
Aug−0.9%40%20
Sep+0.3%55%20
Oct−1.3%55%20
Nov−0.5%55%20
Dec+3.2%70%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1455.7
MFI61.6
ADX34.0
Stochastic %K / %D37.4 / 39.0
Williams %R-67.8
CCI65
TSI / signal16.7 / 16.6
Chaikin money flow0.10
ATR$11.56
Bollinger width11.5%
Volume vs 20-day avg0.54x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$295.83 (+1.5%)
SMA 50$288.88 (+3.9%)
SMA 200$215.10 (+39.5%)
EMA 21$295.87 (+1.4%)
EMA 50$281.89 (+6.5%)
EMA 200$229.29 (+30.9%)
Bollinger upper$312.83 (−4.1%)
Bollinger lower$278.82 (+7.7%)
Parabolic SAR$328.18 (−8.5%)
Open the live chart, 110+ indicators

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

https://www.criver.com

Key executives

NameTitlePayBorn
Birgit GirshickCEO & Director$1.8M1970
Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy$1.3M1974
Victoria L. CreamerCorporate Executive Vice President & Chief People Officer$1.2M1970
Glenn G. ColemanCorporate Executive Vice President & Chief Financial Officer$930,2011968
Michael Gunnar KnellCorporate Senior Vice President & Chief Accounting Officer$912,2251977
Brian F. BathgateCorporate Senior Vice President of European Safety Assessment—1960
Kerry DaileyCorporate Senior VP & Chief Legal Officer——
Mark MintzCorporate EVP, Chief Information Officer & Global Shared Services—1974

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
James C. Foster Chair, President, Chief Executive Officer and Director2023$1.5M$9.1M$1.1M$14.1M
Birgit Girshick Corporate Executive Vice President, Chief Operating Officer2023$704,811$3.0M$442,830$5.0M
Flavia H. Pease Corporate Executive Vice President, Chief Financial Officer2023$621,915$1.7M$324,223$3.8M
Joseph LaPlume Corporate Executive Vice President Corporate Development and Strategy2023$539,000$1.7M$291,810$3.1M
William D. Barbo Corporate Executive Vice President2023$568,144$1.5M$329,977$2.9M

Employees

15k201817k201918k202020k202121k202222k202320k202420k2025

Dividends

Ex-dateAmountPaid
None on file.

Moat model

Weak · Efficient Scale · 2026-06-27
Cost advantage52
Intangibles19
Switching costs34
Network effect40
Efficient scale73
Our component scores (0-100) and overall 40.6; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms